Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Aceso Life Science Group Limited
  6. News
  7. Summary
    474   KYG0070S1066

ACESO LIFE SCIENCE GROUP LIMITED

(474)
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PROMETHERA Biosciences S.A./N.V. announced that it expects to receive €10 million in funding from Hao Tian Development Group Limited

07/13/2020 EST

PROMETHERA Biosciences S.A./N.V. announced that it has entered into an agreement with Hao Tian Development Group Limited (SEHK:474) to issue convertible bonds in the principal amount of €10,000,000 on July 13, 2020. The bonds are fully convertible into preferred shares of the company representing 4.14% stake at a conversion value of €210,300,000. The convertible bonds shall bear a gross interest of 8% per annum on a 365 days basis, payable on the maturity date. The maturity date is the first anniversary of the issue date of the first tranche of the bonds, if no qualified listing is achieved prior to such date. The convertible bonds will constitute direct, unsubordinated and unsecured obligations of the company. The company will receive funding in 2 equal tranches. The first tranche is subject to execution of the JV agreement, the execution and delivery of the IP contribution agreements, the approval from any relevant regulatory authority including the Stock Exchange, reasonably satisfactory result of the due diligence and the final approval from the respective board of directors of the company and investor. Pursuant to the first tranche, the investor shall be entitled to appoint a director to the board of directors of the company. he second tranche is subject to completion of the first tranche of the convertible bonds and company having raised additional funds of not less than €10,000,000 simultaneously.


© S&P Capital IQ 2020
All news about ACESO LIFE SCIENCE GROUP LIMITED
2021Aceso Life Science Group Limited Announces Changes in Composition of the Nomination Com..
CI
2021Aceso Life Science Sees Fiscal H1 Attributable Loss Drop
MT
2021Aceso Life Science Group Limited Reports Earnings Results for the Half Year Ended Septe..
CI
2021Aceso Life Science Group Limited Announces Resignation of Wang Yu as Non-Executive Dire..
CI
2021ACESO LIFE SCIENCE : Selling Stake Worth Nearly $43 Million in Hao Tian International
MT
2021Fong, Tim entered into the Sale and Purchase Agreement to acquire 8.44% stake in Hao Ti..
CI
2021Aceso Life Science Group Limited Announces Executive Changes
CI
2021Aceso Life Science Group Limited Announces Resignation of Li Yao as Non-Executive Direc..
CI
2021Aceso Life Science Group Limited Reports Consolidated Earnings Result for the Year Ende..
CI
2021ACESO LIFE SCIENCE : Supplemental joint announcement discloseable transaction in relation ..
PU
More news
Financials
Sales 2021 98,0 M 12,6 M 12,6 M
Net income 2021 -376 M -48,3 M -48,3 M
Net Debt 2021 2 086 M 268 M 268 M
P/E ratio 2021 -3,59x
Yield 2021 -
Capitalization 1 389 M 178 M 178 M
EV / Sales 2020 -120x
EV / Sales 2021 37,3x
Nbr of Employees 167
Free-Float 37,2%
Chart ACESO LIFE SCIENCE GROUP LIMITED
Duration : Period :
Aceso Life Science Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACESO LIFE SCIENCE GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Managers and Directors
Chi Tak Fok Chief Financial Officer & Executive Director
Ming Sun Chan Independent Non-Executive Director
Kwan Sing Lam Independent Non-Executive Director
Yiu Tong Mak Independent Non-Executive Director
Hai Ying Xu Executive Director
Sector and Competitors